Table 4.
Adverse events of targeted therapy.
| Type of AE | AE Grade | Vemurafenib N = 13 | Dabrafenib N = 6 | Dabrafenib + Trametinib N = 11 |
|---|---|---|---|---|
| Pyrexia | 1 | 2 | 0 | 4 |
| 2 | 1 | 1 | 0 | |
| 3 | 0 | 0 | 1 | |
| Arthralgia | 1 | 4 | 0 | 1 |
| 2 | 1 | 0 | 1 | |
| 3 | 2 | 0 | 1 | |
| Rash | 1 | 5 | 0 | 1 |
| 2 | 1 | 0 | 0 | |
| 3 | 1 | 1 | 0 | |
| Hand-foot syndrome | 1 | 1 | 0 | 0 |
| 2 | 2 | 0 | 1 | |
| 3 | 1 | 0 | 0 | |
| Fatigue | 1 | 4 | 2 | 1 |
| 2 | 1 | 0 | 1 | |
| Pneumonitis | 1 | 0 | 0 | 0 |
| 2 | 0 | 0 | 2 | |
| Loss of appetite | 1 | 1 | 0 | 1 |
| Mucositis oral | 1 | 0 | 1 | 0 |
| Nausea | 1 | 2 | 0 | 0 |
| Alopecia | 1 | 3 | 0 | 0 |
| ALT increased | 1 | 1 | 0 | 0 |
| White blood cell decreased | 1 | 1 | 0 | 0 |
| Anemia | 1 | 0 | 1 | 0 |
| Diarrhea | 1 | 0 | 0 | 1 |
AE, adverse events; ALT, glutamate pyruvic transaminase.